SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT*1) device.
Kubota Vision Initiates PBOS Prospective Study in Patients
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company received Quality Management System - ISO 13485:2016 certification for the design and development of ophthalmic medical devices. ISO 13485 is an internationally recognized safety and quality standard for medical devices. Kubota Pharmaceutical group continues to pursue developing ophthalmic medical devices to satisfy unmet medical needs worldwide.
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of results from a phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with macular atrophy (MA) secondary to Stargardt disease (STGD) in the medical journal British Journal of Ophthalmology.
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision”), formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the signing of an Open Innovation Agreement with LEO Pharma A/S (“LEO Pharma”) to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds discovered by Kubota Vision. LEO Pharma will evaluate the compounds in disease assays for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis.
Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company has achieved over 65% subject enrollment in its ongoing phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease.